Compare TROW & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TROW | BNTX |
|---|---|---|
| Founded | 1937 | 2008 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 24.8B |
| IPO Year | N/A | 2019 |
| Metric | TROW | BNTX |
|---|---|---|
| Price | $104.19 | $94.14 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $106.45 | ★ $137.40 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ 0.40 | N/A |
| EPS | ★ 9.17 | N/A |
| Revenue | ★ $7,205,200,000.00 | $3,698,814,972.00 |
| Revenue This Year | $5.40 | $2.03 |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $11.35 | ★ N/A |
| Revenue Growth | ★ 4.25 | 3.70 |
| 52 Week Low | $77.85 | $81.20 |
| 52 Week High | $118.32 | $129.27 |
| Indicator | TROW | BNTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 42.08 |
| Support Level | $102.58 | $91.32 |
| Resistance Level | $106.06 | $93.76 |
| Average True Range (ATR) | 1.96 | 2.16 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 50.67 | 34.20 |
T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of September, the firm had $1.767 trillion in managed assets, composed of equity (50%), balanced (35%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two-thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.